89bio Announces Appointment of Kathy LaPorte to its Board of Directors
November 03, 2021 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD’s The Liver Meeting 2021
October 25, 2021 16:05 ET
|
89bio, Inc.
SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio to Participate in the Cantor Global Healthcare Conference
September 21, 2021 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021 16:15 ET
|
89bio, Inc.
SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 12, 2021 16:05 ET
|
89bio, Inc.
- Initiated Phase 2b ENLIVEN trial in NASH patients -- Completed enrollment in NASH histology cohort with topline data expected by year-end 2021 - SAN FRANCISCO, Aug. 12, 2021 (GLOBE NEWSWIRE) --...
89bio to Participate in Upcoming Investor Conferences
August 03, 2021 16:15 ET
|
89bio, Inc.
SAN FRANCISCO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH
August 02, 2021 08:30 ET
|
89bio, Inc.
SAN FRANCISCO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio to Participate in Upcoming Investor Conferences
June 16, 2021 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH
June 10, 2021 08:30 ET
|
89bio, Inc.
SAN FRANCISCO, June 10, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 12, 2021 16:05 ET
|
89bio, Inc.
SAN FRANCISCO, May 12, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...